

# Live Attenuated Vaccine-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/L3F4736D502EN.html>

Date: February 2018

Pages: 152

Price: US\$ 3,480.00 (Single User License)

ID: L3F4736D502EN

## Abstracts

### Report Summary

Live Attenuated Vaccine-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Live Attenuated Vaccine industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Live Attenuated Vaccine 2013-2017, and development forecast 2018-2023

Main market players of Live Attenuated Vaccine in United States, with company and product introduction, position in the Live Attenuated Vaccine market

Market status and development trend of Live Attenuated Vaccine by types and applications

Cost and profit status of Live Attenuated Vaccine, and marketing status

Market growth drivers and challenges

The report segments the United States Live Attenuated Vaccine market as:

United States Live Attenuated Vaccine Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South  
Southwest

United States Live Attenuated Vaccine Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Pediatrics  
Adults

United States Live Attenuated Vaccine Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Hospital  
Medical Center  
Others

United States Live Attenuated Vaccine Market: Players Segment Analysis (Company  
and Product introduction, Live Attenuated Vaccine Sales Volume, Revenue, Price and  
Gross Margin):

Astellas Pharma (Japan)  
CSL Limited (Australia)  
Emergent BioSolutions (U.S.)  
GlaxoSmithKline (U.K.)  
Johnson & Johnson (U.S.)  
MedImmune (U.S.)  
Merck & Co (U.S.)  
Pfizer (U.S.)  
Sanofi Pasteur (France)  
Serum Institute of India Pvt (India)

In a word, the report provides detailed statistics and analysis on the state of the  
industry; and is a valuable source of guidance and direction for companies and  
individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF LIVE ATTENUATED VACCINE**

- 1.1 Definition of Live Attenuated Vaccine in This Report
- 1.2 Commercial Types of Live Attenuated Vaccine
  - 1.2.1 Pediatrics
  - 1.2.2 Adults
- 1.3 Downstream Application of Live Attenuated Vaccine
  - 1.3.1 Hospital
  - 1.3.2 Medical Center
  - 1.3.3 Others
- 1.4 Development History of Live Attenuated Vaccine
- 1.5 Market Status and Trend of Live Attenuated Vaccine 2013-2023
  - 1.5.1 United States Live Attenuated Vaccine Market Status and Trend 2013-2023
  - 1.5.2 Regional Live Attenuated Vaccine Market Status and Trend 2013-2023

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Live Attenuated Vaccine in United States 2013-2017
- 2.2 Consumption Market of Live Attenuated Vaccine in United States by Regions
  - 2.2.1 Consumption Volume of Live Attenuated Vaccine in United States by Regions
  - 2.2.2 Revenue of Live Attenuated Vaccine in United States by Regions
- 2.3 Market Analysis of Live Attenuated Vaccine in United States by Regions
  - 2.3.1 Market Analysis of Live Attenuated Vaccine in New England 2013-2017
  - 2.3.2 Market Analysis of Live Attenuated Vaccine in The Middle Atlantic 2013-2017
  - 2.3.3 Market Analysis of Live Attenuated Vaccine in The Midwest 2013-2017
  - 2.3.4 Market Analysis of Live Attenuated Vaccine in The West 2013-2017
  - 2.3.5 Market Analysis of Live Attenuated Vaccine in The South 2013-2017
  - 2.3.6 Market Analysis of Live Attenuated Vaccine in Southwest 2013-2017
- 2.4 Market Development Forecast of Live Attenuated Vaccine in United States 2018-2023
  - 2.4.1 Market Development Forecast of Live Attenuated Vaccine in United States 2018-2023
  - 2.4.2 Market Development Forecast of Live Attenuated Vaccine by Regions 2018-2023

### **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole United States Market Status by Types

- 3.1.1 Consumption Volume of Live Attenuated Vaccine in United States by Types
- 3.1.2 Revenue of Live Attenuated Vaccine in United States by Types
- 3.2 United States Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in New England
  - 3.2.2 Market Status by Types in The Middle Atlantic
  - 3.2.3 Market Status by Types in The Midwest
  - 3.2.4 Market Status by Types in The West
  - 3.2.5 Market Status by Types in The South
  - 3.2.6 Market Status by Types in Southwest
- 3.3 Market Forecast of Live Attenuated Vaccine in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Live Attenuated Vaccine in United States by Downstream Industry
- 4.2 Demand Volume of Live Attenuated Vaccine by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Live Attenuated Vaccine by Downstream Industry in New England
  - 4.2.2 Demand Volume of Live Attenuated Vaccine by Downstream Industry in The Middle Atlantic
  - 4.2.3 Demand Volume of Live Attenuated Vaccine by Downstream Industry in The Midwest
  - 4.2.4 Demand Volume of Live Attenuated Vaccine by Downstream Industry in The West
  - 4.2.5 Demand Volume of Live Attenuated Vaccine by Downstream Industry in The South
  - 4.2.6 Demand Volume of Live Attenuated Vaccine by Downstream Industry in Southwest
- 4.3 Market Forecast of Live Attenuated Vaccine in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF LIVE ATTENUATED VACCINE**

- 5.1 United States Economy Situation and Trend Overview
- 5.2 Live Attenuated Vaccine Downstream Industry Situation and Trend Overview

## **CHAPTER 6 LIVE ATTENUATED VACCINE MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

- 6.1 Sales Volume of Live Attenuated Vaccine in United States by Major Players
- 6.2 Revenue of Live Attenuated Vaccine in United States by Major Players
- 6.3 Basic Information of Live Attenuated Vaccine by Major Players
  - 6.3.1 Headquarters Location and Established Time of Live Attenuated Vaccine Major Players
  - 6.3.2 Employees and Revenue Level of Live Attenuated Vaccine Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 LIVE ATTENUATED VACCINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Astellas Pharma (Japan)
  - 7.1.1 Company profile
  - 7.1.2 Representative Live Attenuated Vaccine Product
  - 7.1.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Astellas Pharma (Japan)
- 7.2 CSL Limited (Australia)
  - 7.2.1 Company profile
  - 7.2.2 Representative Live Attenuated Vaccine Product
  - 7.2.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of CSL Limited (Australia)
- 7.3 Emergent BioSolutions (U.S.)
  - 7.3.1 Company profile
  - 7.3.2 Representative Live Attenuated Vaccine Product
  - 7.3.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Emergent BioSolutions (U.S.)
- 7.4 GlaxoSmithKline (U.K.)
  - 7.4.1 Company profile
  - 7.4.2 Representative Live Attenuated Vaccine Product
  - 7.4.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of GlaxoSmithKline (U.K.)
- 7.5 Johnson & Johnson (U.S.)
  - 7.5.1 Company profile

- 7.5.2 Representative Live Attenuated Vaccine Product
- 7.5.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Johnson & Johnson (U.S.)
- 7.6 MedImmune (U.S.)
  - 7.6.1 Company profile
  - 7.6.2 Representative Live Attenuated Vaccine Product
  - 7.6.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of MedImmune (U.S.)
- 7.7 Merck & Co (U.S.)
  - 7.7.1 Company profile
  - 7.7.2 Representative Live Attenuated Vaccine Product
  - 7.7.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Merck & Co (U.S.)
- 7.8 Pfizer (U.S.)
  - 7.8.1 Company profile
  - 7.8.2 Representative Live Attenuated Vaccine Product
  - 7.8.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Pfizer (U.S.)
- 7.9 Sanofi Pasteur (France)
  - 7.9.1 Company profile
  - 7.9.2 Representative Live Attenuated Vaccine Product
  - 7.9.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Sanofi Pasteur (France)
- 7.10 Serum Institute of India Pvt (India)
  - 7.10.1 Company profile
  - 7.10.2 Representative Live Attenuated Vaccine Product
  - 7.10.3 Live Attenuated Vaccine Sales, Revenue, Price and Gross Margin of Serum Institute of India Pvt (India)

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVE ATTENUATED VACCINE**

- 8.1 Industry Chain of Live Attenuated Vaccine
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF LIVE ATTENUATED VACCINE**

- 9.1 Cost Structure Analysis of Live Attenuated Vaccine
- 9.2 Raw Materials Cost Analysis of Live Attenuated Vaccine
- 9.3 Labor Cost Analysis of Live Attenuated Vaccine
- 9.4 Manufacturing Expenses Analysis of Live Attenuated Vaccine

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF LIVE ATTENUATED VACCINE**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Live Attenuated Vaccine-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/L3F4736D502EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L3F4736D502EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970